AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30296472 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating As Treatment (EAT) intervention
Number of subjects: 307
Study 30296472 — intervention group
Group type: COMPARATOR
Intervention: Control group (treatment as usual)
Number of subjects: 307
Study 30307410 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus plus a single, intraoperative, high-dose (9 mg/kg) rabbit anti-T-lymphocyte globulins (ATLG)
Number of subjects: 206
Study 30307410 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus monotherapy (TAC)
Number of subjects: 206
Study 30307410 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus plus ATLG
Number of subjects: 206
Study 26977624 — intervention group
Group type: EXPERIMENTAL
Intervention: Remaxol (400 ml intravenously, 2 times a day for 7 days)
Number of subjects: 80
Study 26977624 — intervention group
Group type: COMPARATOR
Intervention: Saline with 25%-magnesium sulfate (10 ml) and 4% potassium chloride (10 ml)
Number of subjects: 80
Study 26977624 — intervention group
Group type: EXPERIMENTAL
Intervention: Remaxol
Number of subjects: 80
Study 23680491 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel
Number of subjects: 63
Study 23680491 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 63
Study 22699165 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation program
Number of subjects: 50
Study 22699165 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50
Study 20825615 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL/kg perfluorocarbon
Number of subjects: 24
Study 20825615 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mL/kg perfluorocarbon
Number of subjects: 24
Study 20825615 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mL/kg perfluorocarbon
Number of subjects: 24
Study 17879531 — intervention group
Group type: EXPERIMENTAL
Intervention: Migu Tablet group (MGTG)
Number of subjects: 160
Study 17879531 — intervention group
Group type: EXPERIMENTAL
Intervention: Xianlin Gubao group (XLGBG)
Number of subjects: 160
Study 17879531 — intervention group
Group type: COMPARATOR
Intervention: Leli Calcium group (LCG)
Number of subjects: 160
Study 17879531 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study 16372237 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine enema procedures prior to delivery (264 subjects)
Number of subjects: 534
Study 16372237 — intervention group
Group type: COMPARATOR
Intervention: No enema (270 subjects)
Number of subjects: 534
Study 12376205 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly cisplatin 70 mg/m² (days 1, 8, 15, 29, 36, 43) in combination with escalating doses of paclitaxel (225 mg/m² 4-weekly or 100 mg/m² weekly)
Number of subjects: 49
Study 10102059 — intervention group
Group type: COMPARATOR
Intervention: 0.1 IU/kg/day (0.03 mg/kg/day), administered once daily (Group A)
Number of subjects: 92
Study 10102059 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 IU/kg/day (0.07 mg/kg/day), administered once daily (Group B)
Number of subjects: 92
Study 10102059 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 IU/kg/day (0.07 mg/kg/day), divided into two equal injections given at 12‐hour intervals (Group C)
Number of subjects: 92
Study 7794869 — intervention group
Group type: EXPERIMENTAL
Intervention: Test meal A
Number of subjects: 9
Study 7794869 — intervention group
Group type: EXPERIMENTAL
Intervention: Test meal B
Number of subjects: 9
Study 2221415 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% Intralipid (3 mL/min for 20 min)
Number of subjects: 60
Study 2221415 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose in lactated Ringer's solution
Number of subjects: 60
Study 348222 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 0.1 mg and Morphine 10 mg with Droperidol 2.5 mg
Number of subjects: 240
Study 348222 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 0.1 mg and Morphine 10 mg with Droperidol 5.0 mg
Number of subjects: 240
Study 348222 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 0.1 mg and Morphine 10 mg (without Droperidol)
Number of subjects: 240
Study 30144600 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality preoperative planning
Number of subjects: 30
Study 30144600 — intervention group
Group type: COMPARATOR
Intervention: Traditional preoperative planning
Number of subjects: 30
Study 28486087 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator group (LapSim® VR simulator with haptic feedback)
Number of subjects: 30
Study 28486087 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 26016870 — intervention group
Group type: EXPERIMENTAL
Intervention: MFGM diet (whipping cream, 40 g milk fat/d)
Number of subjects: 57
Study 26016870 — intervention group
Group type: COMPARATOR
Intervention: Control diet (butter oil, 40 g milk fat/d)
Number of subjects: 57
Study 23436260 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg/kg
Number of subjects: 0
Study 23436260 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 4 mg/kg
Number of subjects: 0
Study 23436260 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0
Study 20594878 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (3 mg/kg/h) and Ketamine (0.6 mg/kg/h) with Morphine (0.24 mg/kg/h)
Number of subjects: 44
Study 20594878 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (3 mg/kg/h) and Ketamine (0.6 mg/kg/h) with Fentanyl (0.0036 mg/kg/h)
Number of subjects: 44
Study 20594878 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactate solution (Control)
Number of subjects: 44
Study 19621198 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornithine alpha-ketoglutarate (OKG) 10g daily
Number of subjects: 160
Study 19621198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 19621198 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornithine alpha-ketoglutarate (OKG)
Number of subjects: 160
Study 17293085 — intervention group
Group type: COMPARATOR
Intervention: Mecamylamine (MEC) 0.0 mg/day
Number of subjects: 53
Study 17293085 — intervention group
Group type: COMPARATOR
Intervention: Mecamylamine (MEC) 5.0 mg/day
Number of subjects: 53
Study 17293085 — intervention group
Group type: COMPARATOR
Intervention: Mecamylamine (MEC) 10.0 mg/day
Number of subjects: 53
Study 17293085 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute smoking abstinence
Number of subjects: 53
Study 17293085 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline smoking measures
Number of subjects: 53
Study 15573355 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface-derived autogenous bone graft
Number of subjects: 193
Study 16990657 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low-Calorie Diet (VLCD) for 4 days (1.6 MJ)
Number of subjects: 16
Study 10364862 — intervention group
Group type: EXPERIMENTAL
Intervention: AutoGuard cannula (group AG)
Number of subjects: 100
Study 10364862 — intervention group
Group type: COMPARATOR
Intervention: Conventional Insyte intravenous cannula (group C)
Number of subjects: 100
Study 8759372 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein isolate beverage powder (60 g/d for 28 d)
Number of subjects: 20
Study 8759372 — intervention group
Group type: COMPARATOR
Intervention: Casein supplement
Number of subjects: 20
Study 2007444 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of Prostaglandin E2 (PGE2) administered by intravaginal route in a hydroxyethyl cellulose gel medium
Number of subjects: 0
Study 2007444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7124678 — intervention group
Group type: EXPERIMENTAL
Intervention: Low O2 regimen
Number of subjects: 23
Study 7124678 — intervention group
Group type: COMPARATOR
Intervention: High O2 regimen
Number of subjects: 23
Study 31048444 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate solution (4.2 g in 50 mL of 50 mmol/L) with standard preoperative infusion of normal saline (1.5 L)
Number of subjects: 478
Study 31048444 — intervention group
Group type: COMPARATOR
Intervention: Placebo (50 mL) with standard preoperative infusion of normal saline (1.5 L)
Number of subjects: 478
Study 29402762 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention promoting healthy eating habits and physical activities (12-month duration, includes in-person educational sessions and digital communication via website and text messages)
Number of subjects: 315
Study 29402762 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 315
Study 27609408 — intervention group
Group type: EXPERIMENTAL
Intervention: benralizumab 30 mg Q4W
Number of subjects: 1205
Study 27609408 — intervention group
Group type: EXPERIMENTAL
Intervention: benralizumab 30 mg Q8W
Number of subjects: 1205
Study 27609408 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1205
Study 24606622 — intervention group
Group type: EXPERIMENTAL
Intervention: Online educational modules
Number of subjects: 0
Study 22234043 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy consumption (highest quintile at 18 months)
Number of subjects: 335
Study 22234043 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of at least two dairy serves at both 18 months and 9 years
Number of subjects: 335
Study 22234043 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium, magnesium, and potassium intakes (highest quintiles)
Number of subjects: 335
Study 19662418 — intervention group
Group type: EXPERIMENTAL
Intervention: MDCT with three-dimensional post-processing (3Ds)
Number of subjects: 145
Study 18086760 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training (RET)
Number of subjects: 242
Study 18086760 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (AET)
Number of subjects: 242
Study 18086760 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular aerobic and resistance exercise
Number of subjects: 242
Study 18086760 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 242
Study 15678363 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (75 mg)
Number of subjects: 48
Study 15678363 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (150 mg)
Number of subjects: 48
Study 15678363 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 48
Study 15678363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 12118865 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent auditory task
Number of subjects: 0
Study 12118865 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving-related scene elements
Number of subjects: 0
Study 12118865 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving-unrelated scene elements
Number of subjects: 0
Study 10450639 — intervention group
Group type: EXPERIMENTAL
Intervention: Bionator with anterior extraoral traction and up-and-down elastics
Number of subjects: 20
Study 10450639 — intervention group
Group type: COMPARATOR
Intervention: Bionator and extraoral traction without additional securing of the mandible
Number of subjects: 20
Study 7818116 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous oxycodone (7.9 +/- 1.5 mg)
Number of subjects: 12
Study 7818116 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal oxycodone (30 mg)
Number of subjects: 12
Study 7818116 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxycodone
Number of subjects: 12
Study 2159694 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitors
Number of subjects: 0
Study 30452645 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Promoting Schools components adherence
Number of subjects: 61
Study 29768119 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigatinib (90 to 240 mg total daily) in phase I/II trial; 90 mg once daily in ALTA arm A; 180 mg once daily with 7-day lead-in at 90 mg in ALTA arm B.
Number of subjects: 79
Study 26546241 — intervention group
Group type: EXPERIMENTAL
Intervention: High variety support exercise program for 6 weeks
Number of subjects: 121
Study 26546241 — intervention group
Group type: COMPARATOR
Intervention: Low variety support exercise program for 6 weeks
Number of subjects: 121
Study 24268433 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-conducted (AC) stimulation
Number of subjects: 20
Study 24268433 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-conducted (BC) stimulation
Number of subjects: 20
Study 23110515 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide treated materials (ITMs) including PermaNet 2.0 netting treated with deltamethrin at 55 mg/m2 and targeted interventions (larviciding with Temephos, elimination of breeding sites)
Number of subjects: 970
Study 23110515 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 970
Study 20507292 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab therapy (2.0 grams divided into two doses of 1.0 gram on days 1 and 15)
Number of subjects: 8
Study 20507292 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (not specified dosage or duration)
Number of subjects: 8
Study 17143011 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% triclosan combined with 0.34% chlorhexidine dihydrochloride
Number of subjects: 0
Study 17143011 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0% triclosan
Number of subjects: 0
Study 17143011 — intervention group
Group type: COMPARATOR
Intervention: Reference preparation containing fusidic acid
Number of subjects: 0
Study 16320790 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestin‐only injectable hormonal contraceptive Norethisterone oenanthate 200 mg
Number of subjects: 50
Study 16320790 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-users of progestin‐only injectable contraceptive)
Number of subjects: 50
Study 11952201 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure (VRE) therapy
Number of subjects: 49
Study 11952201 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Exposure (SE) therapy
Number of subjects: 49
Study 11952201 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WL)
Number of subjects: 49
Study 9799042 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 90
Study 9799042 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (20 mg)
Number of subjects: 90
Study 7549332 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 mm corneal tunnel incision
Number of subjects: 62
Study 7549332 — intervention group
Group type: COMPARATOR
Intervention: 5 mm corneal tunnel incision
Number of subjects: 62
Study 7549332 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 62
Study 2693794 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-methyldigoxin (medixin)
Number of subjects: 81
Study 2693794 — intervention group
Group type: EXPERIMENTAL
Intervention: bemecor (digicor)
Number of subjects: 81
Study 358754 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (50-125 mg/day)
Number of subjects: 72
Study 358754 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (50-125 mg/day)
Number of subjects: 72
Study 358754 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 72
Study 358754 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 72
Study 30779375 — intervention group
Group type: EXPERIMENTAL
Intervention: fesoterodine (4 mg/day)
Number of subjects: 120
Study 30779375 — intervention group
Group type: EXPERIMENTAL
Intervention: mirabegron (50 mg/day)
Number of subjects: 120
Study 29455482 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral pedicle screw (UPS) after TLIF technique combined with contralateral percutaneous transfacet screw (PTS) fixation (group A)
Number of subjects: 46
Study 29455482 — intervention group
Group type: COMPARATOR
Intervention: Bilateral pedicle screws (BPS) fixation (group B)
Number of subjects: 46
Study 25563584 — intervention group
Group type: EXPERIMENTAL
Intervention: FES-assisted cycling
Number of subjects: 50
Study 25563584 — intervention group
Group type: COMPARATOR
Intervention: Passive cycling
Number of subjects: 50
Study 23982939 — intervention group
Group type: EXPERIMENTAL
Intervention: CSE‐EVR (combined spinal-epidural anaesthesia) with 0.5 mg per 10 cm height of hyperbaric levobupivacaine and 20 microg fentanyl, followed by 20 mL saline solution injection
Number of subjects: 60
Study 23982939 — intervention group
Group type: COMPARATOR
Intervention: SA (single shot spinal anaesthesia)
Number of subjects: 60
Study 21049267 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (400 μg/kg)
Number of subjects: 21
Study 21049267 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.5 mg/ml and 0.7 mg/ml)
Number of subjects: 21
Study 21049267 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined effects of THC and alcohol
Number of subjects: 21
Study 21049267 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg/ml)
Number of subjects: 21
Study 19968623 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction measured by a single question (Likert 5 scale)
Number of subjects: 106
Study 19968623 — intervention group
Group type: EXPERIMENTAL
Intervention: Harris Hip Score
Number of subjects: 106
Study 16256874 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy for ventricular tachycardia (VT) or ventricular fibrillation (VF)
Number of subjects: 719
Study 16256874 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim hospitalization for congestive heart failure (IH-CHF)
Number of subjects: 719
Study 16256874 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim hospitalization for coronary events (IH-CE)
Number of subjects: 719
Study 12446291 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini‐Mental State Examination
Number of subjects: 0
Study 12446291 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheffield Screening Test for Acquired Language Disorders
Number of subjects: 0
Study 12446291 — intervention group
Group type: EXPERIMENTAL
Intervention: Raven's Coloured Progressive Matrices
Number of subjects: 0
Study 10515402 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline (1 mg q.i.d.)
Number of subjects: 34
Study 10515402 — intervention group
Group type: COMPARATOR
Intervention: Inhaled salbutamol (100, 100, 200 microg at 5 min intervals)
Number of subjects: 34
Study 10515402 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (400 microg, b.i.d.)
Number of subjects: 34
Study 10515402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 8787255 — intervention group
Group type: COMPARATOR
Intervention: Epidural corticosteroids (caudal or lumbar)
Number of subjects: 907
Study 8787255 — intervention group
Group type: COMPARATOR
Intervention: Caudal epidural steroid
Number of subjects: 907
Study 8787255 — intervention group
Group type: COMPARATOR
Intervention: Lumbar epidural steroid
Number of subjects: 907
Study 8787255 — intervention group
Group type: COMPARATOR
Intervention: Epidural corticosteroids
Number of subjects: 907
Study 1799922 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (10 to 20 mg daily)
Number of subjects: 53
Study 1799922 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 to 20 mg daily)
Number of subjects: 53
Study 6274473 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal sodium diet in hypertensive patients
Number of subjects: 42
Study 6274473 — intervention group
Group type: COMPARATOR
Intervention: Normal sodium diet in normotensive subjects
Number of subjects: 42
Study 28643052 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced learning concept
Number of subjects: 20
Study 28643052 — intervention group
Group type: COMPARATOR
Intervention: Conservative training
Number of subjects: 20
Study 26736024 — intervention group
Group type: EXPERIMENTAL
Intervention: TMT+NMES
Number of subjects: 64
Study 26736024 — intervention group
Group type: COMPARATOR
Intervention: Passive control
Number of subjects: 64
Study 25620554 — intervention group
Group type: EXPERIMENTAL
Intervention: Thera-band resistance exercise
Number of subjects: 95
Study 25620554 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine activities)
Number of subjects: 95
Study 23473338 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (to achieve a hemoglobin target of 13 g per deciliter)
Number of subjects: 2278
Study 23473338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2278
Study 23473338 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 2278
Study 21917440 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate 500 μg (FP500) twice-daily
Number of subjects: 17
Study 18455784 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity monitoring
Number of subjects: 125
Study 18455784 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity monitoring with a pedometer
Number of subjects: 125
Study 16880485 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional ventilation debriefing
Number of subjects: 236
Study 16880485 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational debriefing
Number of subjects: 236
Study 16880485 — intervention group
Group type: COMPARATOR
Intervention: No debriefing (control)
Number of subjects: 236
Study 15198477 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol (500 mg/day, n=9)
Number of subjects: 26
Study 15198477 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=9)
Number of subjects: 26
Study 15198477 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD group
Number of subjects: 26
Study 11028729 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 3.75 mg/ml
Number of subjects: 60
Study 11028729 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.3 ml/kg
Number of subjects: 60
Study 9298419 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification (PE)
Number of subjects: 375
Study 9298419 — intervention group
Group type: COMPARATOR
Intervention: Standard extracapsular cataract surgery
Number of subjects: 375
Study 9298419 — intervention group
Group type: EXPERIMENTAL
Intervention: Other ocular disease
Number of subjects: 375
Study 9298419 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative complications
Number of subjects: 375
Study 8291628 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 111
Study 8291628 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 111